1 Wan, P., Xu, D., Zhang, J., Li, Q., Zhang, M., Chen, X. et al. Liver transplantation for biliary atresia: A nationwide investigation from 1996 to 2013 in mainland China. Pediatr Transplant 2016;20:1051-1059
2 Kasahara, M., Umeshita, K., Inomata, Y. & Uemoto, S. Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013;13:1830-1839
3 Kim, J. M., Kim, K. M., Yi, N.-J., Choe, Y. H., Kim, M. S., Suh, K. S. et al. Pediatric liver transplantation outcomes in Korea. Journal of Korean medical science 2013;28:42-47
4 Chen, C. L., Concejero, A., Wang, C. C., Wang, S. H., Lin, C. C., Liu, Y. W. et al. Living donor liver transplantation for biliary atresia: a single-center experience with first 100 cases. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006;6:2672-2679
5 Vannaprasaht, S., Reungjui, S., Supanya, D., Sirivongs, D., Pongskul, C., Avihingsanon, Y. et al. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Clinical therapeutics 2013;35:1762-1769
6 Penninga, L., Møller, C. H., Gustafsson, F., Steinbrüchel, D. A. & Gluud, C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 2010;66:1177-1187
7 Kim, J. S., Aviles, D. H., Silverstein, D. M., Leblanc, P. L. & Matti Vehaskari, V. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005;9:162-169
8 Xue, F., Han, L., Chen, Y., Xi, Z., Li, Q., Xu, N. et al. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients. Pediatr Transplant 2014;18:166-176
9 Iwasaki, K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug metabolism and pharmacokinetics 2007;22:328-335
10 Wan, P., Li, Q., Zhang, J., Shen, C., Luo, Y., Chen, Q. et al. Influence of graft size matching on outcomes of infantile living donor liver transplantation. Pediatr Transplant 2015;19:880-887
11 Yang, T. H., Chen, Y. K., Xue, F., Han, L. Z., Shen, C. H., Zhou, T. et al. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. International journal of clinical practice. Supplement 2015;53-62
12 Chen, Y.-k., Han, L.-z., Xue, F., Shen, C.-h., Lu, J., Yang, T.-h. et al. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. PloS one 2014;9:e109464
13 Xue, F., Zhang, J., Han, L., Li, Q., Xu, N., Zhou, T. et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. Transplantation 2010;89:620-626
14 Hooper, E., Hawkins, D. M., Kowalski, R. J., Post, D. R., Britz, J. A., Brooks, K. C. et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clinical transplantation 2005;19:834-839
15 Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive care medicine 2013;39:165-228
16 Staatz, C. E. & Tett, S. E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical pharmacokinetics 2004;43:623-653
17 Jain, A. B., Fung, J. J., Tzakis, A. G., Venkataramanan, R., Abu-Elmagd, K., Alessiani, M. et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplantation proceedings 1991;23:2763-2766
18 McDiarmid, S. V., Colonna, J. O., Shaked, A., Vargas, J., Ament, M. E. & Busuttil, R. W. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation 1993;55:1328-1332
19 Mancinelli, L. M., Frassetto, L., Floren, L. C., Dressler, D., Carrier, S., Bekersky, I. et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clinical pharmacology and therapeutics 2001;69:24-31
20 Neylan, J. F. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998;65:515-523
21 Min, D. I., Chen, H. Y., Fabrega, A., Ukah, F. O., Wu, Y. M., Corwin, C. et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation 1996;62:1190-1192
22 Bekersky, I., Dressler, D. & Mekki, Q. A. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. Journal of clinical pharmacology 2001;41:176-182
23 Rendic, S. & Di Carlo, F. J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug metabolism reviews 1997;29:413-580
24 Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature genetics 2001;27:383-391
25 Fingas, C. D., Beste, M., Penndorf, V., Sydor, S., Nadalin, S., Bechmann, L. et al. Liver Regeneration-Related Cytokine Profiles in Donors and Recipients Before and After Living-Donor Liver Transplant. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2018;16:554-561
26 Lim, W. X., Cheng, Y. F., Huang, T. L., Chen, T. Y., Tsang, L. L. C., Ou, H. Y. et al. Graft regeneration in pediatric living donor liver transplantation. Transplantation proceedings 2014;46:767-769
27 MacPhee, I. A. M. Pharmacogenetic biomarkers: cytochrome P450 3A5. Clinica chimica acta; international journal of clinical chemistry 2012;413:1312-1317
28 Canaparo, R., Finnström, N., Serpe, L., Nordmark, A., Muntoni, E., Eandi, M. et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clinical and experimental pharmacology & physiology 2007;34:1138-1144
29 Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J. et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular pharmacology 2002;62:162-172
30 Alak, A. M. & Moy, S. Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. Transplantation proceedings 1997;29:2487-2490
31 Iwasaki, K., Shiraga, T., Nagase, K., Tozuka, Z., Noda, K., Sakuma, S. et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug metabolism and disposition: the biological fate of chemicals 1993;21:971-977
32 Christians, U., Kruse, C., Kownatzki, R., Schiebel, H. M., Schwinzer, R., Sattler, M. et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplantation proceedings 1991;23:940-941
33 Gonschior, A. K., Christians, U., Braun, F., Winkler, M., Linck, A., Baumann, J. et al. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). British journal of clinical pharmacology 1994;38:567-571
34 Shiraga, T., Matsuda, H., Nagase, K., Iwasaki, K., Noda, K., Yamazaki, H. et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochemical pharmacology 1994;47:727-735